$NNOX
Nano-X Imaging Ltd. Stock $nnox

$nnox Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024034697 Filed on April 22, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$2.397M	$9.905M	$2.132M
YoY Change	12.43%	15.47%	63.5%
Cost Of Revenue	$4.113M	$16.50M	$3.879M
YoY Change	6.03%	6.72%	37.75%
Gross Profit	-$1.716M	-$6.592M	-$1.747M
YoY Change	-1.77%	-4.19%	15.54%
Gross Profit Margin	-71.59%	-66.55%	-81.94%
Selling, General & Admin	$6.524M	$28.44M	$6.119M
YoY Change	6.62%	-37.67%	-32.37%
% of Gross Profit
Research & Development	$6.812M	$26.05M	$7.095M
YoY Change	-3.99%	-1.73%	11.52%
% of Gross Profit
Depreciation & Amortization	$3.098M	$1.198M	$2.928M
YoY Change	5.81%	32.38%	53.94%
% of Gross Profit
Operating Expenses	$10.67M	$56.00M	$11.91M
YoY Change	-10.4%	-49.47%	-28.22%
Operating Profit	-$12.39M	-$62.59M	-$13.66M
YoY Change	-9.3%	-46.83%	-24.57%
Interest Expense	$360.0K	$1.652M	-$113.0K
YoY Change	-418.58%	109.38%	-60.76%
% of Operating Profit
Other Income/Expense, Net		$1.652M
YoY Change		131954.36%
Pretax Income	-$10.33M	-$61.12M	-$53.87M
YoY Change	-80.83%	-47.73%	143.94%
Income Tax	-$79.00K	-$339.0K	-$1.032M
% Of Pretax Income
Net Earnings	-$10.25M	-$60.78M	-$52.84M
YoY Change	-80.6%	-46.33%	139.79%
Net Earnings / Revenue	-427.53%	-613.59%	-2478.28%
Basic Earnings Per Share		-$1.08
Diluted Earnings Per Share	-$0.18	-$1.08	-$1.01
COMMON SHARES
Basic Shares Outstanding	57.78M shares	56.37K shares	55.09M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$82.38M	$82.38M	$77.62M
YoY Change	6.13%	6.13%	-12.5%
Cash & Equivalents	$56.38M	$56.38M	$38.46M
Short-Term Investments	$26.01M	$26.01M	$39.16M
Other Short-Term Assets	$1.092M	$2.412M	$1.446M
YoY Change	-24.48%	-37.51%	-71.62%
Inventory	$2.356M	$2.356M
Prepaid Expenses	$1.274M		$2.414M
Receivables	$1.484M	$1.484M	$977.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$88.64M	$88.64M	$82.46M
YoY Change	7.49%	7.49%	-13.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.34M	$46.92M	$43.55M
YoY Change	-2.76%	4.95%	11.2%
Goodwill			$7.420M
YoY Change			-87.27%
Intangibles	$80.61M		$91.22M
YoY Change	-11.63%		-10.42%
Long-Term Investments	$0.00	$0.00	$25.20M
YoY Change	-100.0%	-100.0%	-62.86%
Other Assets	$2.163M	$2.490M	$2.867M
YoY Change	-24.56%	-15.1%	142.15%
Total Long-Term Assets	$130.0M	$130.0M	$171.5M
YoY Change	-24.18%	-24.18%	-36.09%
TOTAL ASSETS
Total Short-Term Assets	$88.64M	$88.64M	$82.46M
Total Long-Term Assets	$130.0M	$130.0M	$171.5M
Total Assets	$218.6M	$218.6M	$253.9M
YoY Change	-13.9%	-13.9%	-30.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.303M	$3.303M	$3.619M
YoY Change	-8.73%	-8.73%	15.48%
Accrued Expenses	$3.920M	$4.781M	$12.24M
YoY Change	-67.97%	-63.17%	172.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.490M	$3.490M
YoY Change
Total Short-Term Liabilities	$15.52M	$15.52M	$25.07M
YoY Change	-38.09%	-38.09%	-52.47%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$3.481M
YoY Change		-100.0%	-8.3%
Other Long-Term Liabilities	$612.0K	$4.657M	$483.0K
YoY Change	26.71%	-13.25%	-93.48%
Total Long-Term Liabilities	$7.610M	$4.657M	$12.18M
YoY Change	-37.52%	-47.37%	8.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.52M	$15.52M	$25.07M
Total Long-Term Liabilities	$7.610M	$4.657M	$12.18M
Total Liabilities	$23.13M	$23.13M	$37.25M
YoY Change	-37.9%	-37.9%	-47.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$320.2M		-$259.5M
YoY Change	23.42%		77.45%
Common Stock	$165.0K		$158.0K
YoY Change	4.43%		6.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$195.5M	$195.5M	$216.7M
YoY Change
Total Liabilities & Shareholders Equity	$218.6M	$218.6M	$253.9M
YoY Change	-13.9%	-13.9%	-30.08%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$10.25M	-$60.78M	-$52.84M
YoY Change	-80.6%	-46.33%	139.79%
Depreciation, Depletion And Amortization	$3.098M	$1.198M	$2.928M
YoY Change	5.81%	32.38%	53.94%
Cash From Operating Activities	-$12.51M	-$44.78M	-$12.88M
YoY Change	-2.83%	3.21%	-33.34%
INVESTING ACTIVITIES
Capital Expenditures	$528.0K	$3.303M	-$216.0K
YoY Change	-344.44%	-53.94%	-96.35%
Acquisitions
YoY Change
Other Investing Activities	$2.802M	$38.74M	$10.89M
YoY Change	-74.27%	77.88%	-18.74%
Cash From Investing Activities	$2.274M	$35.43M	$11.11M
YoY Change	-79.52%	142.59%	48.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	33.00K	$27.25M	174.0K
YoY Change	-81.03%	3289.55%	-83.33%
NET CHANGE
Cash From Operating Activities	-12.51M	-$44.78M	-12.88M
Cash From Investing Activities	2.274M	$35.43M	11.11M
Cash From Financing Activities	33.00K	$27.25M	174.0K
Net Change In Cash	-10.21M	$17.85M	-1.599M
YoY Change	538.34%	-163.19%	-85.17%
FREE CASH FLOW
Cash From Operating Activities	-$12.51M	-$44.78M	-$12.88M
Capital Expenditures	$528.0K	$3.303M	-$216.0K
Free Cash Flow	-$13.04M	-$48.08M	-$12.66M
YoY Change	3.0%	-4.9%	-5.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39461
CY2023	dei	Entity Registrant Name EntityRegistrantName	NANO-X IMAGING LTD
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Ofer Tech Park
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	94 Shlomo Shmeltzer Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Petach Tikva
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	4970602
CY2023	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	NNOX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57778628	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1309
CY2023	dei	Auditor Name AuditorName	Kesselman & Kesselman
CY2023	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56377000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38463000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	46000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	26006000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	39161000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	55000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	34000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1484000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	977000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2356000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1274000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2414000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1092000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1446000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	88635000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	82461000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	327000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	66000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42343000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43545000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4573000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1157000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	25198000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	80607000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	91219000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7420000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2163000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2867000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	130013000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	171472000	usd
CY2023Q4	us-gaap	Assets Assets	218648000	usd
CY2022Q4	us-gaap	Assets Assets	253933000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3490000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3303000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3619000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3920000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12240000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	543000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	182000	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	4250000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	861000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	740000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3407000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4043000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15524000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25074000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4045000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3481000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	398000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4089000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2953000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3330000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	612000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	483000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7610000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12179000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	23134000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	37253000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57778628	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	57778628	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55094237	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	55094237	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	165000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	158000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	515887000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	477953000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-305000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1974000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-320233000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-259457000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	195514000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	216680000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	218648000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	253933000	usd
CY2023	us-gaap	Revenues Revenues	9905000	usd
CY2022	us-gaap	Revenues Revenues	8578000	usd
CY2021	us-gaap	Revenues Revenues	1304000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	16497000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	15458000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	2816000	usd
CY2023	us-gaap	Gross Profit GrossProfit	-6592000	usd
CY2022	us-gaap	Gross Profit GrossProfit	-6880000	usd
CY2021	us-gaap	Gross Profit GrossProfit	-1512000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26049000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26507000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17122000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4168000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4376000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7033000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24272000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41254000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34709000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	7420000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	50878000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4488000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20376000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1424000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-8191000	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1182000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	55997000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	110830000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	60046000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-62589000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-117710000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-61558000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-178000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1652000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	789000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-288000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61115000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-116921000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61846000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-339000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3678000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-48000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60776000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113243000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-61798000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.17
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56368	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52235	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48216	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60776000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113243000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-61798000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-178000	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1491000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1367000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-607000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1669000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1367000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-607000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59107000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114610000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62405000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	230746000	usd
CY2021	nnox	Issuance Of Ordinary Shares Value Upon Exercise Of Warrants IssuanceOfOrdinarySharesValueUponExerciseOfWarrants	267000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3333000	usd
CY2021	nnox	Issuance Of Ordinary Shares To Investors Sue To Business Combination And Purchase Of Assets IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets	101510000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	18697000	usd
CY2021	nnox	Unrealized Loss From Availableforsale Securities UnrealizedLossFromAvailableforsaleSecurities	-607000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-61798000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	292148000	usd
CY2022	nnox	Issuance Of Ordinary Shares Value Upon Exercise Of Warrants IssuanceOfOrdinarySharesValueUponExerciseOfWarrants	370000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	579000	usd
CY2022	nnox	Issuance Of Ordinary Shares In Connection With Earnout Liability IssuanceOfOrdinarySharesInConnectionWithEarnoutLiability	953000	usd
CY2022	nnox	Issuance Of Ordinary Under Settlement Agreement With Former Shareholders IssuanceOfOrdinaryUnderSettlementAgreementWithFormerShareholders	18617000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	18623000	usd
CY2022	nnox	Unrealized Loss From Availableforsale Securities UnrealizedLossFromAvailableforsaleSecurities	-1367000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113243000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	216680000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	27139000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	903000	usd
CY2023	nnox	Issuance Of Ordinary Under Settlement Agreement With Former Shareholders IssuanceOfOrdinaryUnderSettlementAgreementWithFormerShareholders	1561000	usd
CY2023	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	1500000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6838000	usd
CY2023	nnox	Unrealized Loss From Availableforsale Securities UnrealizedLossFromAvailableforsaleSecurities	1669000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60776000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	195514000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60776000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113243000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-61798000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6838000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	18623000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	18806000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10612000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10607000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1768000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	7420000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	50878000	usd
CY2023	nnox	Change In Contingent Earnout Liability ChangeInContingentEarnoutLiability	4488000	usd
CY2022	nnox	Change In Contingent Earnout Liability ChangeInContingentEarnoutLiability	20376000	usd
CY2023	us-gaap	Depreciation Depreciation	1198000	usd
CY2022	us-gaap	Depreciation Depreciation	905000	usd
CY2021	us-gaap	Depreciation Depreciation	524000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-377000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3733000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-116000	usd
CY2023	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	-178000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-69000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	47000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10000	usd
CY2023	nnox	Amortization Of Premium Discount And Accrued Interest On Marketable Securities AmortizationOfPremiumDiscountAndAccruedInterestOnMarketableSecurities	-735000	usd
CY2022	nnox	Amortization Of Premium Discount And Accrued Interest On Marketable Securities AmortizationOfPremiumDiscountAndAccruedInterestOnMarketableSecurities	-1398000	usd
CY2021	nnox	Amortization Of Premium Discount And Accrued Interest On Marketable Securities AmortizationOfPremiumDiscountAndAccruedInterestOnMarketableSecurities	216000	usd
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	172000	usd
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	214000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1297000	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	507000	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-74000	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	40000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1940000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1235000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1724000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	251000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	800000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	374000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-153000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	469000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1721000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-8956000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	10410000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-719000	usd
CY2023	nnox	Increase Decrease Operating Lease IncreaseDecreaseOperatingLease	352000	usd
CY2022	nnox	Increase Decrease Operating Lease IncreaseDecreaseOperatingLease	-125000	usd
CY2021	nnox	Increase Decrease Operating Lease IncreaseDecreaseOperatingLease	23000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-37000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-82000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	179000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	129000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	250000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	233000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44777000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43385000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38061000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2859000	usd
CY2023	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	373000	usd
CY2023	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	38287000	usd
CY2022	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	31241000	usd
CY2021	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	10986000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	8454000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	104043000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	822000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2754000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3303000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7171000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23158000	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1010000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	35433000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14606000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-116320000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3796000	usd
CY2023	nnox	Proceeds From Issuance Of Ordinary Shares And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts	27139000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	145000	usd
CY2023	nnox	Payment Due To Settlement Of Contingent Earnout Liabilities PaymentDueToSettlementOfContingentEarnoutLiabilities	790000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	370000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	267000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	903000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	579000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3316000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27252000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	804000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7379000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-60000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-268000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17848000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-28243000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-147012000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38529000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	66772000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	213784000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	56377000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	38529000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	66772000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	147000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7000	usd
CY2023	us-gaap	Dividends And Interest Paid DividendsAndInterestPaid	149000	usd
CY2022	us-gaap	Dividends And Interest Paid DividendsAndInterestPaid	90000	usd
CY2021	us-gaap	Dividends And Interest Paid DividendsAndInterestPaid	13000	usd
CY2021	nnox	Fair Value Of Ordinary Shares Issued As Consideration For Purchase Of Assets FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets	1500000	usd
CY2021	nnox	Fair Value Of Ordinary Shares Issued As Consideration For Business Combinations And Achievement FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinationsAndAchievement	100010000	usd
CY2023	nnox	Issuance Of Ordinary Share In Connections With Earnout Liability IssuanceOfOrdinaryShareInConnectionsWithEarnoutLiability	1561000	usd
CY2022	nnox	Issuance Of Ordinary Share In Connections With Earnout Liability IssuanceOfOrdinaryShareInConnectionsWithEarnoutLiability	953000	usd
CY2022	nnox	Issuance Of Ordinary Shares Under Settlement Agreement With Former Shareholders IssuanceOfOrdinarySharesUnderSettlementAgreementWithFormerShareholders	18617000	usd
CY2021	nnox	Fair Value Of Contingent Consideration Assumed In Business Combinations FairValueOfContingentConsiderationAssumedInBusinessCombinations	47194000	usd
CY2021	nnox	Fair Value Of Contingent Consideration Assumed In Purchase Of Assets FairValueOfContingentConsiderationAssumedInPurchaseOfAssets	1091000	usd
CY2023	nnox	Reclassification Of Earnout Liability To Equity ReclassificationOfEarnoutLiabilityToEquity	1500000	usd
CY2023	nnox	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets1 OperatingLeaseLiabilitiesArisingFromObtainingOperatingRightofUseAssets1	4411000	usd
CY2022	nnox	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets1 OperatingLeaseLiabilitiesArisingFromObtainingOperatingRightofUseAssets1	320000	usd
CY2021	nnox	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets1 OperatingLeaseLiabilitiesArisingFromObtainingOperatingRightofUseAssets1	194000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 — GENERAL:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nano-X Imaging Ltd, an Israeli Company (hereinafter “the Company” or “Nanox IL”), was incorporated on December 20, 2018 and commenced its operations on September 3, 2019.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">In August 2020, the Company completed an IPO and its ordinary shares began to trade on Nasdaq with net proceeds received from the IPO of approximately $169 million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 19, 2019, Nanox IL established Nanox Imaging Inc. (hereinafter “Nanox Japan”), a wholly owned subsidiary in Japan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 25, 2020, Nanox IL established Nano-X Korea Inc. (hereinafter “Nanox Korea”), a wholly owned subsidiary in Korea.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 30, 2021, Nanox IL established Nanox Imaging Inc. (hereinafter “Nanox U.S.”), a wholly owned subsidiary in the United States. On the same date, Nanox U.S. established Nanox MDW Inc. (hereinafter “Nanox MDW”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 2, 2021, Nanox U.S. completed the acquisition of 100% of the shares of USARAD Holdings, Inc. (refer to Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 4, 2021, the Company completed the merger with Zebra Medical Vision Ltd (refer to Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">The Company, together with its subsidiaries, develops a commercial-grade tomographic imaging device with a digital X-ray source, provides teleradiology services and develops artificial intelligence applications designed to be used in real-world medical imaging applications. The Company’s solution, referred to as the Nanox Multi Source System, has two integrated components – “Nanox.ARC” and “Nanox.CLOUD”. Nanox.ARC is a medical tomographic imaging system incorporating the Company’s novel digital X-ray source. Nanox.CLOUD is a platform which employs a matching engine to match medical images to radiologists, provides image repository, connectivity to diagnostic assistive AI systems, billing and reporting. On April 1, 2021, the Company received clearance from the FDA to market the Company’s Nanox Cart X-Ray System, which is the Company’s Single Source System. On April 28, 2023, the Company received clearance from the FDA to market the Nanox.ARC (including the Nanox.CLOUD) as a stationary ‎X-ray ‎system ‎intended to produce tomographic images of the human musculoskeletal system adjunctive to conventional radiography, on adult patients. This device is ‎intended to be used in professional healthcare ‎facilities or ‎radiological ‎environments, such as ‎hospitals, clinics, imaging ‎centers and ‎other medical practices‎ by trained radiographers, ‎radiologists and physicists.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">In August 2022, the Company entered into a supply agreement with Re-medi Co Ltd. in order to integrate Remedi’s two-dimensional (“2D”) imaging systems (using traditional X-ray tubes) to the Nanox.CLOUD and the Nanox.MARKETPLACE, creating a mobile 2D X-ray system that enables remote readings of scans with AI-powered imaging analysis and a global teleradiology solution, which is referred to as the “Nanox.CONNECT.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">The Company has experienced net losses and negative cash flows from operations since its inception. The Company anticipates such losses will continue until its product candidates reach commercial profitability. On July 26, 2023, the Company raised $30 million in a registered direct offering by selling 2.1 million of the Company’s ordinary shares, together with 5 year warrants to purchase up to 2.1 million ordinary shares with an exercise price of $19.00 per share at a combined purchase price of $14.00 per share. The net proceeds of the offering were approximately $27.1 million Based on the Company’s activities during the year ended December 31, 2023, the Company has sufficient funds for its plans for the next twelve months from the issuance of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Current Impact of geopolitical tensions and the start of the military conflict between Russia and Ukraine</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">The Company’s business may materially be affected by conditions in the financial markets and economic conditions in the U.S., Europe, Asia and, to a lesser extent, elsewhere in the world. 2023 was characterized by significant volatility in global markets, driven by investor concerns over inflation, rising interest rates, slowing economic growth and geopolitical uncertainty. Inflation across many key economies reached generational highs, prompting central banks to take monetary policy tightening actions that are likely to create headwinds to economic growth. Continued global supply chain disruption, including due to China’s recurrent restrictions and the ongoing war between Russia and Ukraine, are also contributing to mounting inflationary pressure. In 2022, in the U.S., annual inflation rose to the highest level in over 40 years. Concurrently, Europe experienced high year-over-year inflation. In response to rising inflation, the Federal Reserve raised the federal funds target range and the European Central Bank raised rates. While several key economic factors, including employment, wage growth and household savings, have demonstrated resilience, the U.S. economic contraction in 2023 has opened a debate among economists as to whether the U.S. has entered, or in the near term will enter, a recession.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">U.S., Israel and global economies and markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. Although the length and impact of the ongoing military conflicts are highly unpredictable, the ongoing conflict in Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">As a result, sanctions and penalties have been levied by the United States, European Union and other countries against Russia. Russian military actions and the resulting sanctions could have a negative impact on supply chains, the Company’s MSaaS agreements relating to Russia and Belarus or the region and adversely affect the global economy and financial markets. Any of the abovementioned factors could affect the Company’s business, prospects, financial condition, and operating results. The extent and duration of the military actions, sanctions and resulting market disruptions are impossible to predict, but could be substantial.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b>c.</b></td><td style="text-align: justify"><b>The security situation in Israel</b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The Company’s headquarters and several manufacturing and R&D facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. The Company continues to maintain contingency plans with backup manufacturing and assembly locations for key products and components. During the year ended December 31, 2023, the impact of this war on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation, or expansion of such war.</p>
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	27100000	usd
CY2022	us-gaap	Credit Derivative Term1 CreditDerivativeTerm1	P40Y
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates in the preparation of financial statements</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company’s consolidated financial statements. As applicable to these consolidated financial statements, the most significant estimates relate to goodwill impairment, impairment of long-lives assets, useful lives of intangible assets, income tax, legal and other contingencies and share-based payments. The Company bases its estimates on historical experience, known trends and events and various other factors that the Company believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</p>
CY2023	nnox	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	7420000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	50878000	usd
CY2022Q1	nnox	Private Held Amount PrivateHeldAmount	1010000	usd
CY2023	nnox	Salary Percentage SalaryPercentage	0.0833	pure
CY2023	us-gaap	Other Expenses OtherExpenses	1024000	usd
CY2022	us-gaap	Other Expenses OtherExpenses	1251000	usd
CY2021	us-gaap	Other Expenses OtherExpenses	846000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	26006000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	26311000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-305000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	64359000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	66333000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1974000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	26006000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	64359000	usd
CY2023Q2	us-gaap	Cash Cash	290000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	45392	shares
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>u.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of Credit Risks</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, marketable securities and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The Company’s cash and cash equivalents and restricted cash are invested with major banks in Israel, the United States and Korea. Generally, these investments may be redeemed upon demand and the Company believes that the financial institutions that hold the Company’s cash balances are financially sound and, accordingly, bear minimal risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The Company’s accounts receivable is derived primarily from sales to the Company’s teleradiology business segment located mainly in the United States. Concentration of credit risk with respect to accounts receivable is mitigated by the fact that trade accounts receivables is typically due upon the issuance of invoice for services rendered.</p>
CY2021Q4	nnox	Purchase Consideration PurchaseConsideration	315000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Purchase ContractWithCustomerAssetPurchase	970000	usd
CY2021Q4	nnox	Remaining Service Periods RemainingServicePeriods	P4Y
CY2023	nnox	Determined Estimated Useful Life Period DeterminedEstimatedUsefulLifePeriod	P10Y
CY2021Q3	us-gaap	Compensating Balance Amount CompensatingBalanceAmount	3000000	usd
CY2021Q3	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.06	pure
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	51243000	usd
CY2023	nnox	Goodwill Impairment Charge GoodwillImpairmentCharge	7055000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	58298000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7420000	usd
	nnox	Goodwill Assigned Amount GoodwillAssignedAmount	365000	usd
	nnox	Internal Cash Flows Forecasts InternalCashFlowsForecasts	P7Y
	nnox	Long Term Future Growth Rate LongTermFutureGrowthRate	0.03	pure
	nnox	Discount Rate DiscountRate	0.227	pure
CY2023Q4	us-gaap	Acquisition Costs AcquisitionCosts	7055000	usd
CY2023Q4	nnox	Growth Percentage GrowthPercentage	0.279	pure
CY2022Q4	nnox	Assigned Amount AssignedAmount	51243000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P5Y
CY2023Q4	nnox	Percentage Of Discount Rate PercentageOfDiscountRate	0.22	pure
CY2022Q4	nnox	Carrying Value Percentage CarryingValuePercentage	0.1161	pure
CY2022	nnox	Asset Impairment Charge AssetImpairmentCharge	14338000	usd
CY2022Q2	us-gaap	Goodwill Not Allocated Amount GoodwillNotAllocatedAmount	36905000	usd
CY2023	nnox	Increase Decrease On Growth Rate IncreaseDecreaseOnGrowthRate	0.005	pure
CY2022	nnox	Increase Decrease On Growth Rate IncreaseDecreaseOnGrowthRate	0.005	pure
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	1000000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	2900000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	38463000	usd
CY2022	nnox	Restricted Bank Deposit RestrictedBankDeposit	66000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y18D
CY2023Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	103594000	usd
CY2022Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	103594000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	22987000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12375000	usd
CY2023Q4	us-gaap	Assets Net AssetsNet	80607000	usd
CY2022Q4	us-gaap	Assets Net AssetsNet	91219000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	10607000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10498000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9959000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9959000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	39584000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	80607000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1667000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	689000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2356000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	45034000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	45208000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2691000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1663000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42343000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43545000	usd
CY2023	us-gaap	Depreciation Depreciation	1198000	usd
CY2022	us-gaap	Depreciation Depreciation	905000	usd
CY2021	us-gaap	Depreciation Depreciation	524000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1297000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	172000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	214000	usd
CY2020Q4	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	6314000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	56377000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4906000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1138000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y5M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M7D
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	56377000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	38529000	usd
CY2023	nnox	Leases Square Description LeasesSquareDescription	As of December 31, 2023, the Company has several operating building and car lease agreements:In the second half of 2023, the company started leasing two office floors and parking spaces on Petah Tikva and at the end of the year moved the employees to this location.The company leases approximately 3080 squaremeters (1540 each floor). The lease agreement is effective through October 2028 with an option to extend the lease term through the second lease term, additional 5 years. The company decided that the lease term for the lease components will include both the Initial Lease Term and the Second Lease Term meaning effective through October 2033.The average monthly payment for this agreement is approximately $57 thousand.The Company’s principal executive offices were located in a leased facility in Neve Ilan, Israel until moved to Petah Tikva in December 2023. The monthly rent payment for all the lease premises in Neve-Ilan, Israel in 2023 was approximately $39 thousand.Company leases vehicles to some of its employees. The lease agreement is effective through July 2026 and the monthly payment in 2023 was approximately $13 thousand.Nanox Korea leases 3 vehicles to some employees. 2 of these 3 lease agreements expired in August 2023 and November 2023, respectively. The third lease agreement is effective through February 2024. The monthly payment for these agreements in 2023 was approximately $4 thousand.Nanox Korea leases an apartment for its employees. The lease agreement expired in November 2023.
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2023	us-gaap	Payments For Fees PaymentsForFees	57000	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	18000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1121000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	937000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	72000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1121000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1009000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1446000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1231000	usd
CY2023	nnox	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets OperatingLeaseLiabilitiesArisingFromObtainingOperatingRightofUseAssets	4411000	usd
CY2022	nnox	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets OperatingLeaseLiabilitiesArisingFromObtainingOperatingRightofUseAssets	320000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4573000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1157000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	861000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	740000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4045000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1212	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0584	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1051000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	820000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	851000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	879000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	778000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3862000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8241000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3335000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4906000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	662000	usd
CY2022	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	102000	usd
CY2022	nnox	Revenue Recognized In The Reported Period RevenueRecognizedInTheReportedPeriod	-184000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	580000	usd
CY2023	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	176000	usd
CY2023	nnox	Revenue Recognized In The Reported Period RevenueRecognizedInTheReportedPeriod	-213000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	543000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	398000	usd
CY2023Q4	nnox	Related Party Balances RelatedPartyBalances	8000	usd
CY2022Q4	nnox	Related Party Balances RelatedPartyBalances	89000	usd
CY2023	nnox	Share Based Compensation Arrangement By Share Based Payment Award Options Stock Options Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsStockOptionsTerm	P10Y
CY2023	nnox	Employment Agreement Description EmploymentAgreementDescription	The service agreement was effective as of March 1, 2020 and has been extended by mutual agreement of the parties several times, until terminated at December 31, 2021.
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	12000	usd
CY2023	us-gaap	Lease Income LeaseIncome	7000	usd
CY2021Q3	us-gaap	Long Term Debt Term LongTermDebtTerm	P3Y
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	3800000	usd
CY2021Q3	nnox	Annual Interest Rate AnnualInterestRate	0.01149	pure
CY2023Q2	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	8000000	usd
CY2023	us-gaap	Payments For Deposits PaymentsForDeposits	5000000	usd
CY2023	us-gaap	Other Income OtherIncome	3000000	usd
CY2023	us-gaap	Other Commitments Description OtherCommitmentsDescription	The Company paid a civil penalty in the amount of $650 recorded on Other expenses (income)and was permanently enjoined from violating Section 17(a)(2) of the Securities Act of 1933 (the “Securities Act”) and Section 13(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rules 12b-20 and 13a-1 thereunder. Mr. Poliakine paid disgorgement of $240, together with prejudgment interest of $27, paid a civil penalty of $150, and was permanently enjoined from violating Section 17(a)(2) of the Securities Act and aiding and abetting any violation of Section 13(a) of the Exchange Act and Rules 12b-20 and 13a-1 thereunder.
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	1260000	usd
CY2023Q2	nnox	Loss Contingency New Claims Amount LossContingencyNewClaimsAmount	25000000	usd
CY2023	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.03	pure
CY2023	us-gaap	Payments For Royalties PaymentsForRoyalties	50000	usd
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57778628	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55094237	shares
CY2023Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	2142858	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	19
CY2019Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1220446	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15721000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y10M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee	545105	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	11.22
CY2023	nnox	Percentage Of Granted Options Vested PercentageOfGrantedOptionsVested	0.25	pure
CY2023Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	35500	shares
CY2023	us-gaap	Restricted Stock Expense RestrictedStockExpense	642000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5115910	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.19
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	545105	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.22
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	286141	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.02
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	153480	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	19.36
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5221394	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.34
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5112	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3621783	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.43
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5110	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	14800000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	38000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	55000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	68000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	38000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	55000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	68000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-3357000	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-57000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-377000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-376000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-59000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-377000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3733000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-116000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-339000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3678000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-48000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	61115000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	116921000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	61846000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2023	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	14056000	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	26892000	usd
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	14225000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-333000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	261000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	110000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10434000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11467000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6571000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1550000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	4361000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	4343000	usd
CY2023	nnox	Effective Income Tax Rate Reconciliation Goodwill Impairment EffectiveIncomeTaxRateReconciliationGoodwillImpairment	1566000	usd
CY2022	nnox	Effective Income Tax Rate Reconciliation Goodwill Impairment EffectiveIncomeTaxRateReconciliationGoodwillImpairment	11702000	usd
CY2023	nnox	Effective Income Tax Rate Reconciliation Change In Earnout Liability EffectiveIncomeTaxRateReconciliationChangeInEarnoutLiability	942000	usd
CY2022	nnox	Effective Income Tax Rate Reconciliation Change In Earnout Liability EffectiveIncomeTaxRateReconciliationChangeInEarnoutLiability	4686000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	776000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	631000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3373000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-339000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3678000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-48000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	43699000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	38967000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3771000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4027000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	376000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	740000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1147000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1507000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	532000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	50500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44266000	usd
CY2023Q4	nnox	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets	1069000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19185000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19562000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	30246000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	24704000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30246000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24704000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30246000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24704000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24704000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5542000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30246000	usd
CY2023	us-gaap	Revenues Revenues	9905000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-62589000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1652000	usd
CY2023	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-178000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-61115000	usd
CY2023	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	1198000	usd
CY2023	nnox	Change In Obligation In Earnout Liabilities ChangeInObligationInEarnoutLiabilities	-4488000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	7420000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	6838000	usd
CY2023Q4	us-gaap	Assets Assets	218648000	usd
CY2023	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	3303000	usd
CY2022	us-gaap	Revenues Revenues	8578000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-117710000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	789000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-116921000	usd
CY2022	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	11512000	usd
CY2022	nnox	Change In Obligation In Earnout Liabilities ChangeInObligationInEarnoutLiabilities	-20376000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	50878000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	18623000	usd
CY2022Q4	us-gaap	Assets Assets	253933000	usd
CY2022	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	8181000	usd
CY2021	us-gaap	Revenues Revenues	1304000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-61558000	usd
CY2021	nnox	Financial Expense FinancialExpense	-288000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-61846000	usd
CY2021	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	2292000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	18806000	usd
CY2021Q4	us-gaap	Assets Assets	363170000	usd
CY2021	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	26017000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent		usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	46916000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	44702000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	39160000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60776000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113243000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-61798000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56368	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52235	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48216	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.17
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4455301	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2312443	shares
CY2023	nnox	Outstanding Options OutstandingOptions	5171394	shares
CY2022	nnox	Outstanding Options OutstandingOptions	5065910	shares
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings		usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.17
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax		usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	nnox	Change In Contingent Earnout Liability ChangeInContingentEarnoutLiability		usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments		usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments		usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2022	nnox	Proceeds From Issuance Of Ordinary Shares And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts		usd
CY2021	nnox	Proceeds From Issuance Of Ordinary Shares And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts		usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2022	nnox	Payment Due To Settlement Of Contingent Earnout Liabilities PaymentDueToSettlementOfContingentEarnoutLiabilities		usd
CY2021	nnox	Payment Due To Settlement Of Contingent Earnout Liabilities PaymentDueToSettlementOfContingentEarnoutLiabilities		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	nnox	Fair Value Of Ordinary Shares Issued As Consideration For Purchase Of Assets FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets		usd
CY2022	nnox	Fair Value Of Ordinary Shares Issued As Consideration For Purchase Of Assets FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets		usd
CY2023	nnox	Fair Value Of Ordinary Shares Issued As Consideration For Business Combinations And Achievement FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinationsAndAchievement		usd
CY2022	nnox	Fair Value Of Ordinary Shares Issued As Consideration For Business Combinations And Achievement FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinationsAndAchievement		usd
CY2021	nnox	Issuance Of Ordinary Share In Connections With Earnout Liability IssuanceOfOrdinaryShareInConnectionsWithEarnoutLiability		usd
CY2023	nnox	Issuance Of Ordinary Shares Under Settlement Agreement With Former Shareholders IssuanceOfOrdinarySharesUnderSettlementAgreementWithFormerShareholders		usd
CY2021	nnox	Issuance Of Ordinary Shares Under Settlement Agreement With Former Shareholders IssuanceOfOrdinarySharesUnderSettlementAgreementWithFormerShareholders		usd
CY2023	nnox	Fair Value Of Contingent Consideration Assumed In Business Combinations FairValueOfContingentConsiderationAssumedInBusinessCombinations		usd
CY2022	nnox	Fair Value Of Contingent Consideration Assumed In Business Combinations FairValueOfContingentConsiderationAssumedInBusinessCombinations		usd
CY2023	nnox	Fair Value Of Contingent Consideration Assumed In Purchase Of Assets FairValueOfContingentConsiderationAssumedInPurchaseOfAssets		usd
CY2022	nnox	Fair Value Of Contingent Consideration Assumed In Purchase Of Assets FairValueOfContingentConsiderationAssumedInPurchaseOfAssets		usd
CY2022	nnox	Reclassification Of Earnout Liability To Equity ReclassificationOfEarnoutLiabilityToEquity		usd
CY2021	nnox	Reclassification Of Earnout Liability To Equity ReclassificationOfEarnoutLiabilityToEquity		usd
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies		usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2023	nnox	Restricted Bank Deposit RestrictedBankDeposit		usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55094237	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57778628	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2021	nnox	Effective Income Tax Rate Reconciliation Goodwill Impairment EffectiveIncomeTaxRateReconciliationGoodwillImpairment		usd
CY2021	nnox	Effective Income Tax Rate Reconciliation Change In Earnout Liability EffectiveIncomeTaxRateReconciliationChangeInEarnoutLiability		usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards		usd
CY2022Q4	nnox	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.17
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001795251

Files In Submission

Name	View Source	Status
0001213900-24-034697-index-headers.html	Edgar Link	pending
0001213900-24-034697-index.html	Edgar Link	pending
0001213900-24-034697.txt	Edgar Link	pending
0001213900-24-034697-xbrl.zip	Edgar Link	pending
f20f2023ex12-1_nanoximaging.htm	Edgar Link	pending
f20f2023ex12-2_nanoximaging.htm	Edgar Link	pending
f20f2023ex13-1_nanoximaging.htm	Edgar Link	pending
f20f2023ex13-2_nanoximaging.htm	Edgar Link	pending
f20f2023ex15-1_nanoximaging.htm	Edgar Link	pending
f20f2023ex2-1_nanoximaging.htm	Edgar Link	pending
f20f2023ex8-1_nanoximaging.htm	Edgar Link	pending
f20f2023ex97-1_nanoximaging.htm	Edgar Link	pending
f20f2023_nanoximaging.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nnox-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
nnox-20231231_cal.xml	Edgar Link	unprocessable
nnox-20231231_lab.xml	Edgar Link	unprocessable
f20f2023_nanoximaging_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nnox-20231231_def.xml	Edgar Link	unprocessable
nnox-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNOX
Nano-X Imaging Ltd. Stock $nnox

2023 Q4 Form 20-F Financial Statement

#000121390024034697 Filed on April 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNOX Nano-X Imaging Ltd. Stock $nnox

2023 Q4 Form 20-F Financial Statement

#000121390024034697 Filed on April 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNOX
Nano-X Imaging Ltd. Stock $nnox